Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent Radiotherapy and Weekly Chemotherapy for Postoperative Locoregional Recurrence of Esophageal Squamous Cell Carcinoma
NCT02325986Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Mar 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluorouracil and cisplatin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Sun Yat-sen University. Primary endpoint: Overall Response Rate at 8 weeks. Status: unknown.
02
Drugs
fluorouracilcisplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT02325986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02325986.